- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04838769
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (VAPEUR RCT)
Water Vapor Thermotherapy vs. Combination Pharmacotherapy for Symptomatic Benign Prostatic Hyperplasia Refractory to Alpha Blocker Monotherapy in Sexually Active Men: A Multicenter Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
STUDY OBJECTIVE - To compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
STUDY DESIGN - Multicenter open-label randomized controlled parallel-group post-market trial.
STUDY TREATMENTS AND RANDOMIZATION - Subjects will be randomly assigned to REZŪM or dual drug therapy treatments; 1:1 randomization via the electronic data capture (EDC) system. Both treatments are commercially available. Subjects randomized to receive the REZŪM treatment will receive standardized treatment and subjects randomized to dual drug therapy will receive the local formulary preferred choice of urinary selective alpha blocker and 5-alpha reductase inhibitor.
VISIT SCHEDULE - Study visits are at: enrollment/baseline, treatment, 3 months, 6 months, and yearly follow-up through 2 years.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline Beaudoint
- Phone Number: +32479904163
- Email: Caroline.Beaudoint@bsci.com
Study Contact Backup
- Name: Teresa Takle-Flach
- Phone Number: +19529306000
- Email: Teresa.Takle-Flach@bsci.com
Study Locations
-
-
-
Melbourne, Australia
- Recruiting
- Epworth Healthcare
-
Principal Investigator:
- Paul Anderson, Dr.
-
Wahroonga, Australia
- Not yet recruiting
- Australian Clinical Trials
-
Principal Investigator:
- James Symons, Dr.
-
-
-
-
-
Aix-en-Provence, France
- Recruiting
- Centre Hospitalier du Pays d'Aix
-
Principal Investigator:
- Marc Fourmarier, Dr.
-
Angers, France
- Recruiting
- CHU d'Angers
-
Principal Investigator:
- Souhil Lebdai, Pr.
-
Bordeaux, France
- Recruiting
- CHU de Bordeaux
-
Principal Investigator:
- Grégoire Robert, Pr.
-
Créteil, France
- Not yet recruiting
- CHU Henri Mondor
-
Principal Investigator:
- Alexandre de la Taille, Pr.
-
Grenoble, France
- Recruiting
- CHU Grenoble
-
Principal Investigator:
- Quentin Franquet, Dr.
-
Lille, France
- Recruiting
- Centre Hospitalier Universitaire de Lille
-
Principal Investigator:
- Jonathan Olivier, Dr.
-
Lille, France
- Recruiting
- Hôpital Privé La Louvière
-
Principal Investigator:
- Charles Ballereau, Dr.
-
Lyon, France
- Recruiting
- Hospices Civils de Lyon
-
Principal Investigator:
- Hakim Fassi-Fehri, Dr.
-
Nice, France
- Recruiting
- CHU de Nice
-
Principal Investigator:
- Matthieu Durand, Pr.
-
Paris, France
- Recruiting
- Hopital Cochin
-
Principal Investigator:
- Nicolas Barry Delongchamps, Pr.
-
Paris, France
- Recruiting
- Institut Mutualiste Montsouris
-
Principal Investigator:
- Eric Barret, Dr.
-
Paris, France
- Recruiting
- Hôpital Bichat
-
Principal Investigator:
- Evanguelos Xylinas, Pr.
-
Paris, France
- Not yet recruiting
- Fondation Hôpital Saint-Joseph
-
Principal Investigator:
- Quentin Manach, Dr.
-
Perigueux, France
- Recruiting
- Hôpital privé Francheville
-
Principal Investigator:
- Richard Mallet, Dr.
-
Quint-Fonsegrives, France
- Recruiting
- Clinique La Croix du Sud
-
Principal Investigator:
- Ambroise Salin, Dr.
-
Rennes, France
- Recruiting
- CHU de Rennes
-
Principal Investigator:
- Romain Mathieu, Pr.
-
Rouen, France
- Recruiting
- CHU de Rouen
-
Principal Investigator:
- Jean-Nicolas Cornu, Pr.
-
Rouen, France
- Recruiting
- Clinique Saint Hilaire
-
Principal Investigator:
- Ismaël Galliot, Dr.
-
Saint-Grégoire, France
- Recruiting
- Centre Hospitalier Privé Saint Grégoire
-
Principal Investigator:
- Sébastien Vincendeau, Dr.
-
Toulouse, France
- Recruiting
- Clinique Pasteur
-
Principal Investigator:
- Vincent Misrai, Dr.
-
Toulouse, France
- Recruiting
- CHU de Toulouse
-
Principal Investigator:
- Florian Laclergerie, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Sexually active male subjects ≥ 45 years of age who have persistent non-neurogenic lower urinary tract symptoms refractory to first-line treatment with single agent Alpha Adrenoceptor Antagonist therapy
- Subject is willing and able to answer all domains of MSHQ
- Completed IPSS questionnaire with score ≥ 13 within 6 months prior to enrollment
- Peak urinary flow rate (Qmax): ≤ 15 ml/sec with minimum voided volume of ≥ 150 ml within 6 months prior to enrollment
- Post-void residual (PVR) ≤250 ml within 6 months prior to enrollment
- Prostate volume ≥ 30 ml as measured by transrectal ultrasound or Magnetic Resonance Imaging within 3 months prior to enrollment
- Subject is willing and capable of providing informed consent
- Subject is willing and capable of participating in all visits associated with this study at an approved clinical study site and at the intervals defined by this Clinical Investigational Plan (CIP)
- France subjects only: subjects must be affiliated to national security insurance
Exclusion Criteria:
- Inability to participate in full duration of study
- Prior surgical treatment for BPH
- Increased risk of bleeding
- Presence of Genitourinary Cancer or other pelvic cancer
- Functional issues with bladder
- Presence of active infection in genitourinary tract
- Structural and Anatomic issues with urinary tract and renal function
- Concomitant Drug Therapy
- Temporal restraints and risks for general anaesthesia or comorbidity that would elevate risk of participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: REZŪM
Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use (IFU). The REZŪM System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men with a prostate volume ≥ 30 ml. The REZŪM System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe. 1:1 randomization will occur via the electronic data capture (EDC) system. |
Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
|
Active Comparator: Dual Drug Therapy
Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor.
This arm will therefore represent local standard of care.
|
Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor.
This arm will therefore represent local standard of care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Prostate Symptom Score (IPSS) change
Time Frame: From Baseline to 12 months
|
Primary Statistical Hypothesis: Change in IPSS score will be compared between groups.
IPSS score ranges from 0 to 35 with higher scores indicating worse symptoms.
|
From Baseline to 12 months
|
Male Sexual Health Questionnaire (MSHQ) total score change
Time Frame: From Baseline to 12 months
|
Change in MHSQ score will be compared between groups.
MHSQ score ranges from 0 to 125 with higher scores indicating better outcomes.
|
From Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Progression
Time Frame: End of available follow-up, up to 24 months
|
Disease progression, defined as occurrence of any of the following:
|
End of available follow-up, up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Romain Mathieu, Professor, CHU Rennes, Hôpital Pontchaillou
- Principal Investigator: Evanguelos Xylinas, Ass. Prof., Hôpital Bichat
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Adrenergic alpha-Antagonists
- 5-alpha Reductase Inhibitors
Other Study ID Numbers
- U0693
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia (BPH)
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Medi-Tate Ltd.CompletedBenign Prostatic Hyperplasia (BPH)Spain, Belgium, Italy, Switzerland, United Kingdom
-
GemVax & KaelCompletedBenign Prostatic Hyperplasia (BPH)Korea, Republic of
-
University of Kansas Medical CenterEnrolling by invitationBenign Prostatic Hyperplasia | BPHUnited States
-
Brooklyn Urology Research GroupAmerican Medical Systems; Richard Wolf Medical Instruments Corporation (RWMIC)CompletedBenign Prostatic Hyperplasia (BPH)United States
-
Daniel Stephan EngelerCompletedBenign Prostatic Hyperplasia (BPH)Switzerland
-
HistoSonics, Inc.WithdrawnBenign Prostatic Hyperplasia (BPH)
-
Watson PharmaceuticalsCompletedBenign Prostatic Hyperplasia (BPH)United States
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Lawson Health Research InstituteGyrus ACMI, Inc.CompletedBenign Prostatic Hyperplasia | BPHCanada
Clinical Trials on REZŪM
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia (BPH)China
-
Chinese University of Hong KongRecruiting